Coincidence of acquired factor-X deficiency and disseminated intravascular coagulation in patients with acute nonlymphoblastic leukemia.
Systematic clotting studies were performed in 157 patients with de novo acute nonlymphoblastic leukemia (ANLL) prior to treatment. Sixteen patients had disseminated intravascular coagulation (DIC). Three of the patients with DIC (two with M3, one with M5 leukemia) had a marked isolated factor-X deficiency (factor X:C 21%, 33%, and 41%, respectively). Another four patients had a mild isolated factor-X deficiency (factor X:C 55%-68%). In these seven patients the remaining liver-synthesized clotting factors (factors II, VII, IX, V) as well as serum albumin and cholinesterase were within the normal range. Liver disease or vitamin-K deficiency could therefore be excluded. In none of the 141 patients without DIC was a marked isolated factor X deficiency observed; two patients had moderately reduced factor X:C levels but normal liver-synthesized proteins. Induction treatment led to the control of DIC with an almost parallel increase of fibrinogen and factor X up to normal in all patients with factor-X deficiency who achieved complete remission. In one patient, recurrence of leukemia was associated with reoccurrence of DIC and marked factor-X deficiency. We conclude that there is a coincidence of isolated factor-X deficiency and DIC in some patients with ANLL. In some patients, this factor-X deficiency may be severe enough to contribute to the bleeding tendency.
Pabinger
I
I
First Department of Medicine, University of Vienna, Austria.
Bettelheim
P
P
Dudczak
R
R
Hinterberger
W
W
Kyrle
P A
PA
Niessner
H
H
Schwarzinger
I
I
Speiser
W
W
Lechner
K
K
D000328:Adult; D000368:Aged; D003561:Cytarabine / Q000627:therapeutic use; D003630:Daunorubicin / Q000627:therapeutic use; D004211:Disseminated Intravascular Coagulation / Q000097:blood / Q000150:complications*; D005170:Factor X / Q000378:metabolism; D005171:Factor X Deficiency / Q000097:blood / Q000150:complications*; D005260:Female; D005340:Fibrinogen / Q000378:metabolism; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000097:blood / Q000150:complications* / Q000188:drug therapy; D008297:Male; D008875:Middle Aged
D003561:Cytarabine; D005170:Factor X; D005340:Fibrinogen; D003630:Daunorubicin